SCHEDULE: ARK Investment Management Boosts 10x Genomics Stake to 10.39%

ARK Investment Management LLC and Catherine D. Wood have disclosed a beneficial ownership of 10.39% in 10x Genomics, Inc. Class A Common Stock.

Summary

• ARK Investment Management LLC and Catherine D. Wood reported beneficial ownership of 11,887,396 shares of 10x Genomics, Inc. Class A Common Stock.
• This ownership represents 10.39% of the Class A Common Stock outstanding.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
• The securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of the issuer.
• ARK Investment Management LLC holds sole voting power over 11,051,595 shares and sole dispositive power over 11,887,396 shares.
• Catherine D. Wood holds shared voting power over 11,329,218 shares and shared dispositive power over 11,887,396 shares.
• ARK Innovation ETF, a series of a Delaware statutory trust, is identified as a client of ARK Investment Management LLC with an interest in these securities exceeding 5 percent.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a prominent investment firm like ARK Investment Management and its CEO, Catherine D. Wood, in 10x Genomics, Inc. is generally perceived as a positive signal of confidence in the company's prospects, although the filing itself is purely informational regarding ownership.

Positives

• The disclosure of a significant beneficial ownership stake (10.39%) by a prominent investment firm like ARK Investment Management and its CEO, Catherine D. Wood, can be viewed as a vote of confidence in 10x Genomics, Inc.'s prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders of 10x Genomics, Inc. may view the significant beneficial ownership by ARK Investment Management and Catherine D. Wood as a positive indicator of institutional confidence in the company's long-term value.

Key Dates

Keywords

10x Genomics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, Biotechnology, Genomics